ABL1 K356dup

CI-VAR-00002118Explore in graph →CIViC 3010

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive2
ABL1 K356dup	Dasatinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID10734 K356dup was observed in an imatinib resistant CML. After switch to dasatinib, the patient regained deep molecular response. Therefore, K356dup seems to be resistant to imatinib and susceptible to dasa… (full text at CIViC) PMID 25998099 · Gniot et al., 2012 · Open in CIViC	civic
ABL1 K356dup	Imatinib	Predictive	C	Supports Resistance	3	submitted	EID8107 K356dup was observed in an imatinib resistant CML. After switch to dasatinib, the patient regained deep molecular response. Therefore, K356dup seems to be resistant to imatinib and susceptible to dasa… (full text at CIViC) PMID 25998099 · Gniot et al., 2012 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.